1. Stone C.A., Wenger H.C., Ludden C.T., Stavorski J.M., Ross C.A. Antiserotonin-anthihistaminic properties of cyproheptadine. J. Pharmacol. Exp. Ther. 131: 73, 1961.
2. Gilbert J.C., Goldbert L.I. Characterization by cyproheptadine of the dopamine-induced contraction in canine isolated arteries. J. Pharmacol. Exp. Ther. 193: 435, 1975.
3. Krieger D.T. Cyproheptadine: drug therapy for Cushing’s disease. In: Muller E.E. (Eds.), Neuroactive drugs in endocrinology. Elsevier/North-Holland, Biomedical Press, 1980, p. 361.
4. Jones M.T., Birmingham M., Gillham B., Holmes M., Smith T. The effect of cyproheptadine on the release of corticotrophin-releasing factor. Clin. Endocrinol. (Oxf.) 10: 203, 1979.
5. Krieger D.T. Physiopathology of Cushing’s disease. Endocr. Rev. 4: 22, 1983.